Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors

Journal of Neuro-Oncology

Volumn 109, Issue 1, 2012, Pages 105-114

  Thompson, Eric M ^a   Guillaume, Daniel J ^a   Dósa, Edit ^a   Li, Xin ^b   Nazemi, Kellie J ^c   Gahramanov, Seymur ^a   Hamilton, Bronwyn E ^a   Neuwelt, Edward A ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Brain tumor; DCE MRI; DSC MRI; Ferumoxytol; Pediatric

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; FERUMOXYTOL; GADOLINIUM; GADOTERIDOL; LOMUSTINE; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; ANAPLASTIC OLIGOASTROCYTOMA; ARTICLE; ASTROCYTOMA; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; CANCER SURGERY; CHEMORADIOTHERAPY; CHILD; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; DYNAMIC SUSCEPTIBILITY WEIGHTED CONTRAST NUCLEAR MAGNETIC RESONANCE IMAGING; EXTRACELLULAR SPACE; EXTRAVASCULAR SPACE; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; MALE; MEDULLOBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PILOCYTIC ASTROCYTOMA; PROSPECTIVE STUDY; SCHOOL CHILD; TUMOR GROWTH;

ADOLESCENT; BLOOD VOLUME; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; CHILD; CHILD, PRESCHOOL; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; FERUMOXYTOL; FOLLOW-UP STUDIES; HEMATINICS; HETEROCYCLIC COMPOUNDS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; ORGANOMETALLIC COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84864282730     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0872-x     Document Type: Article

References (29)

1. DA Haas-Kogan A Banerjee TY Poussaint M Kocak MD Prados JR Geyer M Fouladi A Broniscer JE Minturn IF Pollack RJ Packer JM Boyett LE Kun 2011 Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas Neuro Oncol 13 298 306 10.1093/neuonc/noq202 21339191 10.1093/neuonc/noq202 1:CAS:528:DC%2BC3MXktl2ls7k%3D
2. C Meyzer F Dhermain D Ducreux JL Habrand P Varlet C Sainte-Rose C Dufour J Grill 2010 A case report of pseudoprogression followed by complete remission after proton-beam irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI Radiat Oncol 5 9 10.1186/1748-717X-5-9 20132555 10.1186/1748-717X-5-9
3. US Food and Drug Administration. FDA Application: Ferumoxytol. Available at http://wwwaccessdatafdagov/scripts/opdlisting/oopd/OOPD-Results-2cfm?Index- Number=338411. Accessed 17 May 2011
4. E Dosa DJ Guillaume M Haluska CA Lacy BE Hamilton JM Njus WD Rooney DF Kraemer LL Muldoon EA Neuwelt 2011 Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol Neuro Oncol 13 251 260 10.1093/neuonc/noq172 21163809 10.1093/neuonc/noq172 1:CAS:528:DC%2BC3MXisV2nsrw%3D
5. EA Neuwelt CG Varallyay S Manninger D Solymosi M Haluska MA Hunt G Nesbit A Stevens M Jerosch-Herold PM Jacobs JM Hoffman 2007 The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study Neurosurgery 60 601 611 17415196 10.1227/01.NEU.0000255350.71700.37 (discussion 611-602)
6. CG Varallyay LL Muldoon S Gahramanov YJ Wu JA Goodman X Li MM Pike EA Neuwelt 2009 Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model J Cereb Blood Flow Metab 29 853 860 10.1038/jcbfm.2008.162 19142191 10.1038/jcbfm.2008.162 1:CAS:528:DC%2BD1MXjsl2hsbc%3D
7. S Gahramanov AM Raslan LL Muldoon BE Hamilton WD Rooney CG Varallyay JM Njus M Haluska EA Neuwelt 2011 Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility- weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study Int J Radiat Oncol Biol Phys 79 514 523 10.1016/j.ijrobp.2009.10.072 20395065 10.1016/j.ijrobp.2009.10.072
8. Gahramanov S, Muldoon LL, Li X, Neuwelt EA Improved Perfusion MR Imaging Assessment of Intracerebral Tumor Blood Volume and Antiangiogenic Therapy Efficacy in a Rat Model with Ferumoxytol. Radiology 261:796-804. doi: 10.1148/radiol.11103503
9. HA Haroon DL Buckley TA Patankar GR Dow SA Rutherford D Baleriaux A Jackson 2004 A comparison of Ktrans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas J Magn Reson Imaging 19 527 536 10.1002/jmri.20045 15112301 10.1002/jmri.20045 (Pubitemid 38619914)
10. TF Patankar HA Haroon SJ Mills D Baleriaux DL Buckley GJ Parker A Jackson 2005 Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? A AJNR Am J Neuroradiol 26 2455 2465 16286385
11. SJ Mills C Soh CJ Rose S Cheung S Zhao GJ Parker A Jackson 2010 Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging-derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme AJNR Am J Neuroradiol 31 549 553 10.3174/ajnr.A1844 19850765 10.3174/ajnr.A1844 1:STN:280:DC%2BC3c7ot1ertw%3D%3D
12. D Brandsma L Stalpers W Taal P Sminia MJ van den Bent 2008 Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 453 461 10.1016/S1470-2045(08)70125-6 18452856 10.1016/S1470-2045(08)70125-6 (Pubitemid 351597795)
13. CTEP (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
14. SG Wetzel S Cha G Johnson P Lee M Law DL Kasow SD Pierce X Xue 2002 Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study Radiology 224 797 803 12202717 10.1148/radiol.2243011014 (Pubitemid 34919816)
15. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223-232 doi: 10.1002/(SICI)1522-2586(199909)10:3<223::AID- JMRI2>3.0.CO;2-S [pii] (Pubitemid 29463104)
16. AE Evans RD Jenkin R Sposto JA Ortega CB Wilson W Wara IJ Ertel S Kramer CH Chang SL Leikin, et al. 1990 The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone J Neurosurg 72 572 582 10.3171/jns.1990.72.4.0572 2319316 10.3171/jns.1990.72.4.0572 1:STN:280:DyaK3c3gsVSiuw%3D%3D (Pubitemid 20113683)
17. RJ Gilbertson 2004 Medulloblastoma: signalling a change in treatment Lancet Oncol 5 209 218 10.1016/S1470-2045(04)01424-X 15050952 10.1016/S1470-2045(04)01424-X (Pubitemid 38391216)
18. AA Brandes E Franceschi A Tosoni V Blatt A Pession G Tallini R Bertorelle S Bartolini F Calbucci A Andreoli G Frezza M Leonardi F Spagnolli M Ermani 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197 10.1200/JCO.2007.14.8163 18445844 10.1200/JCO.2007.14.8163
19. JS Weinstein CG Varallyay E Dosa S Gahramanov B Hamilton WD Rooney LL Muldoon EA Neuwelt 2010 Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review J Cereb Blood Flow Metab 30 15 35 10.1038/jcbfm.2009.192 19756021 10.1038/jcbfm.2009.192 1:CAS:528:DC%2BC3cXos1Wj
20. M Benesch M Windelberg W Sauseng V Witt G Fleischhack H Lackner H Gadner U Bode C Urban 2008 Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors Ann Oncol 19 807 813 10.1093/annonc/mdm510 18056650 10.1093/annonc/mdm510 1:STN:280: DC%2BD1c3gsVOgsw%3D%3D (Pubitemid 351461055)
21. AK Liu ME Macy NK Foreman 2009 Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas Int J Radiat Oncol Biol Phys 75 1148 1154 10.1016/j.ijrobp.2008.12.032 19857784 10.1016/j.ijrobp.2008.12.032 1:CAS:528:DC%2BD1MXhtlWitL%2FF
22. S Cha L Yang G Johnson A Lai MH Chen T Tihan M Wendland WP Dillon 2006 Comparison of microvascular permeability measurements, K(trans), determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas AJNR Am J Neuroradiol 27 409 417 16484420 1:STN:280:DC%2BD28%2Fps1Cntw%3D%3D (Pubitemid 44897852)
23. SJ Mills TA Patankar HA Haroon D Baleriaux R Swindell A Jackson 2006 Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 27 853 858 16611778 1:STN:280: DC%2BD283gsVGmug%3D%3D (Pubitemid 44897736)
24. PR Lockman RK Mittapalli KS Taskar V Rudraraju B Gril KA Bohn CE Adkins A Roberts HR Thorsheim JA Gaasch S Huang D Palmieri PS Steeg QR Smith 2010 Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer Clin Cancer Res 16 5664 5678 10.1158/1078-0432.CCR-10-1564 20829328 10.1158/1078-0432.CCR-10-1564 1:CAS:528:DC%2BC3cXhsFamtL3F
25. JU Harrer GJ Parker HA Haroon DL Buckley K Embelton C Roberts D Baleriaux A Jackson 2004 Comparative study of methods for determining vascular permeability and blood volume in human gliomas J Magn Reson Imaging 20 748 757 10.1002/jmri.20182 15503330 10.1002/jmri.20182 (Pubitemid 39426068)
26. GZ Ferl L Xu M Friesenhahn LJ Bernstein DP Barboriak RE Port 2010 An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab Magn Reson Med 63 1366 1375 10.1002/mrm.22335 20432307 10.1002/mrm.22335
27. M Law R Young J Babb M Rad T Sasaki D Zagzag G Johnson 2006 Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade AJNR Am J Neuroradiol 27 1975 1982 17032878 1:STN:280:DC%2BD28ngtVChtw%3D%3D (Pubitemid 44556520)
28. M Lu MH Cohen D Rieves R Pazdur 2010 FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease Am J Hematol 85 315 319 10.1002/ajh.21656 20201089 1:CAS:528:DC%2BC3cXmslCisbw%3D
29. BE Hamilton GM Nesbit E Dosa S Gahramanov B Rooney EG Nesbit J Raines EA Neuwelt 2011 Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging Am J Roentgenol 197 981 988 10.2214/AJR.10.5992 10.2214/AJR.10.5992